
Mahmoud Aljurf
@aljurf100
Hematology & HSCT Program. King Faisal Specialist Hospital & Research Center. Riyadh- Saudi Arabia. #bmtsm #leusm #BMFSM #lymsm
ID: 835587356812062720
25-02-2017 20:28:45
8,8K Tweet
2,2K Followers
40 Following

Overexcited for this piece out in The Lancet Haematology 👉 a huge collaboration on behalf of the CMWP of the The EBMT led by DrDonalMcLornan and an incredible global panel of experts: how to deal with germline predisposition in MDS undergoing HSCT. authors.elsevier.com/c/1h~Ie_rV3GEO…

Happy to announce that the TxID Special Edition on infections in patients with heme malignancies and recipients of cellular therapies is now available! Sincere thanks to all the authors for their contributions--lots of high-yield, timely information in here! Gabrielle Haeusler


NEW from Rahul Banerjee, MD, FACP David Maloney & colleagues: Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic Blood Advances Immortal time bias = if pts don't live longer (thanks to CAR T), secondary malignancy won't be observed #cancer #immunotherapy




Dr Syed Osman Ahmed showing the disparities in access to #CART Cells across the globe during the joint #WBMT The EBMT session at #EBMT2024 Ibrahim Yakoub-Agha Mahmoud Aljurf World Health Organization (WHO)


مركز الأبحاث acknowledged Kure.ai David Wald for ongoing collaborations in the Kingdom.



Pleased to share our latest work on a rare and indolent form of lymphoma, Duodenal-type Follicular Lymphoma. Mahmoud Aljurf Riad El Fakih Ruah Alyamany | روى اليماني pubmed.ncbi.nlm.nih.gov/39246163/




📣 We are proud to announce the new open-access EU CAR-T Handbook, now available in a digital format on our website. GoCART_Coalition European Hematology Association This updated version includes new developments in CAR-T according to the latest clinical data and regulatory advancements.


💡 Have you seen this recent publication in Bone Marrow Transplantation? 📰 Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice

Had a wonderful experience listening to Mehdi Hamadani, MD talk in #Kansas! Simple, crisp, and straight to the point. Always a pleasure to hear him speak! #Auto role in #lymphoma




Kikking off 2nd day of CART-Cell Preceptorship at KFSH&RC Great talks, enriched interactive discussions,very good learning experience and great hospitality Thank to Mahmoud Aljurf Ayman Saad مستشفى الملك فيصل التخصصي ومركز الأبحاث مؤسسة ومركز الحسين للسرطان


Check out our recent reveiw "Programmed death inhibitors in CNS B-cell lymphoma: A literature review " مستشفى الملك فيصل التخصصي ومركز الأبحاث Thanks to Riad El Fakih and boss Mahmoud Aljurf share.google/sCIjA1D40TqGjR…